Clearside Biomedical Inc. (CLSD)
Clearside Biomedical Statistics
Share Statistics
Clearside Biomedical has 77.28M shares outstanding. The number of shares has increased by 1.49% in one year.
| Shares Outstanding | 77.28M |
| Shares Change (YoY) | 1.49% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 12.63% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,919 |
| FTD / Avg. Volume | 1.9% |
Short Selling Information
The latest short interest is 500.8K, so 0.65% of the outstanding shares have been sold short.
| Short Interest | 500.8K |
| Short % of Shares Out | 0.65% |
| Short % of Float | 0.66% |
| Short Ratio (days to cover) | 2.67 |
Valuation Ratios
The PE ratio is -2.04 and the forward PE ratio is -1.63. Clearside Biomedical's PEG ratio is 0.18.
| PE Ratio | -2.04 |
| Forward PE | -1.63 |
| PS Ratio | 42.14 |
| Forward PS | 0.6 |
| PB Ratio | -1.8 |
| P/FCF Ratio | -2.84 |
| PEG Ratio | 0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Clearside Biomedical.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of -0.02.
| Current Ratio | 4.44 |
| Quick Ratio | 4.44 |
| Debt / Equity | -0.02 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | -2.95 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $52,000 |
| Profits Per Employee | $-1,073,500 |
| Employee Count | 32 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -35.61% in the last 52 weeks. The beta is 2.04, so Clearside Biomedical's price volatility has been higher than the market average.
| Beta | 2.04 |
| 52-Week Price Change | -35.61% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 49.03 |
| Average Volume (20 Days) | 206,798 |
Income Statement
In the last 12 months, Clearside Biomedical had revenue of 1.66M and earned -34.35M in profits. Earnings per share was -0.47.
| Revenue | 1.66M |
| Gross Profit | 1.51M |
| Operating Income | -28.88M |
| Net Income | -34.35M |
| EBITDA | -24.35M |
| EBIT | -24.57M |
| Earnings Per Share (EPS) | -0.47 |
Balance Sheet
The company has 20.02M in cash and 703K in debt, giving a net cash position of 19.32M.
| Cash & Cash Equivalents | 20.02M |
| Total Debt | 703K |
| Net Cash | 19.32M |
| Retained Earnings | -355.27M |
| Total Assets | 25.13M |
| Working Capital | 16.48M |
Cash Flow
In the last 12 months, operating cash flow was -24.7M and capital expenditures 0, giving a free cash flow of -24.7M.
| Operating Cash Flow | -24.7M |
| Capital Expenditures | n/a |
| Free Cash Flow | -24.7M |
| FCF Per Share | -0.33 |
Margins
Gross margin is 91.05%, with operating and profit margins of -1735.7% and -2064.42%.
| Gross Margin | 91.05% |
| Operating Margin | -1735.7% |
| Pretax Margin | -2064.42% |
| Profit Margin | -2064.42% |
| EBITDA Margin | -1463.16% |
| EBIT Margin | -1735.7% |
| FCF Margin | -1484.25% |
Dividends & Yields
CLSD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CLSD is $5, which is 488.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 488.2% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -21.57 |
| Piotroski F-Score | 3 |